Xiangyi Meng, PhD
- 4Articles
- 12.5KReads1
- 2008–2011Active
- 9Collaborators
- 21Citations2
About
Xiangyi Meng, PhD, has published extensively on Alzheimer's disease, focusing on the use of rivastigmine and its safety, efficacy, and tolerability in patients, including those switching from donepezil. Meng's work, published between 2008 and 2011, addresses predictors of treatment response and long-term outcomes in dementia care. The research primarily appears in Psychiatrist.com journals and includes collaboration with colleagues such as Carl H. Sadowsky and Barbara Koumaras.
Publications
Predictors of Sustained Response to Rivastigmine in Patients With Alzheimer's Disease: A Retrospective Analysis
June 16, 2011
Switching From Oral Donepezil to Rivastigmine Transdermal Patch in Alzheimer's Disease: 20-Week Extension Phase Results
October 28, 2010
1 Read counts for articles published before 2020 may include some non-human traffic.
2 Citation counts provided by Crossref.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
